PDC-APB, or 3-pentadecyl-1,2-phenylene bis(4-(4-aminophenyl)butanoate),[1] is a drug candidate under evaluation to determine if it might protect against contact dermatitis caused by urishiol from poison ivy, poison oak, and poison sumac.

[2][3][4] The compound is one of a class of compounds developed through University of Mississippi research[5] by Mahmoud ElSohly, Waseem Gul, and Mohammad Khalid Ashfaq.

[1] Work on the compound is ongoing under Hapten Sciences,[6] who licensed the university's research in 2010.

[5] The compound has been evaluated in two Phase I clinical trials, and a third Phase I randomized controlled trial, with a secondary objective of evaluating the effect of treatment on urishiol sensitivity, is due to be completed in December 2022.

[7][needs update]